Evidence map›Paper›PMID 27986085›Full record

ArticleRespiratory research2016

Evidence for harm reduction in COPD smokers who switch to electronic cigarettes.

Riccardo Polosa, Jaymin Bhagwanji Morjaria, Pasquale Caponnetto, Umberto Prosperini, Cristina Russo, Alfio Pennisi, Cosimo Marcello Bruno

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Respiratory research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Smoking cessation and vaccination.European respiratory review : an official journal of the European Respiratory Society · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Vaping-Associated Lung Injury: A Review.Medicina (Kaunas, Lithuania) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Riccardo PolosaDipartimento di Medicina Clinica e Sperimentale, University of Catania, Catania, Italy.
Jaymin Bhagwanji MorjariaDepartment of Respiratory Medicine, Royal Brompton & Harefield Hospital Foundation Trust, Harefield Hospital, Hill End Road, Harefield, UB9 6JH, UK. j.morjaria@rbht.nhs.uk.
Pasquale CaponnettoDipartimento di Medicina Clinica e Sperimentale, University of Catania, Catania, Italy.
Umberto ProsperiniOspedale "San Vincenzo" - ASP Messina, Taormina (ME), Italy.
Cristina RussoMCAU ARNAS Garibaldi, Catania, Italy.
Alfio PennisiU.F. Malattie Apparato Respiratorio, Casa di Cura Musumeci-Gecas, Gravina di Catania, Italy.
Cosimo Marcello BrunoDipartimento di Medicina Clinica e Sperimentale, University of Catania, Catania, Italy.
University of Catania · ITFondazione Vincenzo Pansadoro · ITHarefield Hospital · GBOspedale Garibaldi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElectronic cigarettes (ECs) are battery-operated devices designed to vaporise nicotine, which may help smokers quitting or reducing their tobacco consumption. There is a lack of data on the health effects of EC use among smokers with COPD and whether regular use results in improvement in subjective and objective COPD outcomes. We investigated long-term changes in objective and subjective respiratory outcomes in smokers with a diagnosis of COPD who quit or reduced substantially their tobacco consumption by supplementing with or converting only to ECs use.

methodsWe conducted a retrospective chart review of patients with COPD to identify those reporting regular daily use of ECs on at least two follow-up visits at 12- (F/up1) and 24-months (F/up2). Regularly smoking COPD patients were included as a reference group.

resultsA marked reduction in cigarette consumption was observed in ECs users. A significant reduction in COPD exacerbations was reported in the COPD EC user group, their mean (±SD) decreasing from 2.3 (±1) at baseline to 1.8 (±1; p = 0.002) and 1.4 (±0.9; p < 0.001) at F/up1 and F/up2 respectively. A significant reduction in COPD exacerbations was also observed in ECs users who also smoked conventional cigarettes (i.e. 'dual users'). COPD symptoms and ability to perform physical activities improved statistically in the EC group at both visits, with no change in the control group.

conclusionsThese findings suggest that ECs use may aid smokers with COPD reduce their cigarette consumption or remain abstinent, which results in marked improvements in annual exacerbation rate as well as subjective and objective COPD outcomes.

Indexed as

Electronic Nicotine Delivery SystemsHarm ReductionRisk Reduction BehaviorVapingAgedCigarette SmokingDisease ProgressionExercise ToleranceFemaleForced Expiratory VolumeHumansItalyLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveCOPDElectronic cigaretteSmoking cessationTobacco harm reduction

Identifiers

PMID27986085
PMCPMC5162097
OpenAlexW2566095111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.